481TiP Checkmate 722: A phase 3 trial of nivolumab with chemotherapy or ipilimumab vs chemotherapy in epidermal growth factor receptor (EGFR)-mutation, T790M-negative stage IV or recurrent non-small cell lung cancer (NSCLC) after EGFR tyrosine kinase inhibitor (TKI) therapy

Phase 3 ◽

481TiP Checkmate 722: A phase 3 trial of nivolumab with chemotherapy or ipilimumab vs chemotherapy in epidermal growth factor receptor (EGFR)-mutation, T790M-negative stage IV or recurrent non-small cell lung cancer (NSCLC) after EGFR tyrosine kinase inhibitor (TKI) therapy

Annals of Oncology ◽

10.1016/s0923-7534(21)00639-6 ◽

2016 ◽

Vol 27 ◽

pp. ix154-ix155

Author(s):

K. Nakagawa ◽

J.C.-H. Yang ◽

K. Park ◽

Y. Ohe ◽

Y.-L. Wu ◽

...

Keyword(s):

Lung Cancer ◽

Egfr Mutation ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Stage Iv ◽

Small Cell ◽

Small Cell Lung ◽

Phase 3 ◽

Does the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor differ according to the type of EGFR mutation in non-small cell lung cancer?

The Korean Journal of Internal Medicine ◽

10.3904/kjim.2016.190 ◽

2017 ◽

Vol 32 (3) ◽

pp. 422-428 ◽

Cited By ~ 1

Author(s):

Yong Won Choi ◽

Jin-Hyuk Choi

Keyword(s):

Lung Cancer ◽

Growth Factor ◽

Egfr Mutation ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Does the Adjuvant Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Change the Natural History of Resected EGFR Mutation-Positive Non-Small Cell Lung Cancer? Is it for Prime Time?

SSRN Electronic Journal ◽

10.2139/ssrn.3967074 ◽

2021 ◽

Author(s):

Hyun Ae Jung ◽

Jinyeong Lim ◽

Se-Hoon Lee ◽

Je-Gun Joung ◽

Yeong Jeong Jeon ◽

...

Keyword(s):

Lung Cancer ◽

Egfr Mutation ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Prime Time ◽

Small Cell Lung ◽

History Of ◽

Neutrophil to lymphocyte ratio (NLR) as a predictive marker of response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) in EGFR mutation-positive non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.e19117 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. e19117-e19117

Author(s):

Gayatri Vaidyanathan ◽

Grace K. Dy ◽

Petr Starostik ◽

Shiva Dibaj

Keyword(s):

Lung Cancer ◽

Egfr Mutation ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Predictive Marker ◽

Small Cell ◽

Small Cell Lung ◽

Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations

Investigational New Drugs ◽

10.1007/s10637-019-00732-4 ◽

2019 ◽

Vol 37 (6) ◽

pp. 1207-1217

Author(s):

Makoto Nishio ◽

Haruyasu Murakami ◽

Yuichiro Ohe ◽

Toyoaki Hida ◽

Hiroshi Sakai ◽

...

Keyword(s):

Lung Cancer ◽

Phase I Study ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Egfr Mutations ◽

Third Generation ◽

Small Cell Lung ◽

Efficacy of the Irreversible ErbB Family Blocker Afatinib in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI)–Pretreated Non–Small-Cell Lung Cancer Patients with Brain Metastases or Leptomeningeal Disease

Journal of Thoracic Oncology ◽

10.1097/jto.0000000000000380 ◽

2015 ◽

Vol 10 (1) ◽

pp. 156-163 ◽

Cited By ~ 150

Author(s):

Petra Hoffknecht ◽

Amanda Tufman ◽

Thomas Wehler ◽

Theo Pelzer ◽

Rainer Wiewrodt ◽

...

Keyword(s):

Lung Cancer ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Leptomeningeal Disease ◽

Small Cell Lung ◽

Lung Cancer Patients ◽

Erbb Family Blocker ◽

Clinical Significance of Sequential Treatment with Afatinib in the Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Treatment of Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a3935 ◽

2019 ◽

Author(s):

N. Kobayashi ◽

H. Aiko ◽

C. Kamimaki ◽

N. Mikami ◽

S. Kubo ◽

...

Keyword(s):

Lung Cancer ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Epidermal Growth ◽

Tki Treatment ◽

Egfr Mutant

Pneumonitis in advanced non-small-cell lung cancer (NSCLC) patients (pts) treated with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI): Meta-analysis of 153 trial cohorts with 15,713 pts.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.e21223 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. e21223-e21223

Author(s):

Chong Hyun Suh ◽

Hyesun Park ◽

Kyung Won Kim ◽

Junhee Pyo ◽

Hiroto Hatabu ◽

...

Keyword(s):

Lung Cancer ◽

Kinase Inhibitor ◽

Meta Analysis ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Epidermal Growth ◽

Nsclc Patients

Abstract 697: Improvement in quality and length of life following treatment with mifepristone in women with stage IV non-small cell lung cancer, positive for the epidermal growth factor receptor (EGFR) mutation, that previously progressed on targeted therapy

10.1158/1538-7445.am2020-697 ◽

2020 ◽

Author(s):

Jerome H. Check ◽

Diane Check ◽

Trina Poretta ◽

James Aikins ◽

Carrie Wilson

Keyword(s):

Lung Cancer ◽

Targeted Therapy ◽

Egfr Mutation ◽

Growth Factor Receptor ◽

Stage Iv ◽

Small Cell ◽

Small Cell Lung ◽

Epidermal Growth ◽

Length Of Life

Cytokeratin 19 Fragment Predicts the Efficacy of Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor in Non–Small-Cell Lung Cancer Harboring EGFR Mutation

Journal of Thoracic Oncology ◽

10.1097/jto.0b013e31828c3929 ◽

2013 ◽

Vol 8 (7) ◽

pp. 892-898 ◽

Cited By ~ 24

Author(s):

Kosuke Tanaka ◽

Akito Hata ◽

Reiko Kaji ◽

Shiro Fujita ◽

Takehiro Otoshi ◽

...

Keyword(s):

Lung Cancer ◽

Receptor Tyrosine Kinase ◽

Egfr Mutation ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Cytokeratin 19 ◽

Small Cell Lung ◽

Epidermal Growth ◽

Cytokeratin 19 Fragment